Nyrada Inc. (ASX:NYR) Reports Half-Year Financial Results
Nyrada Inc. (ASX:NYR) reports a 64% revenue decline and a $2.46m loss for the half-year, while advancing its leading drug candidate to clinical trials.
Category: Healthcare
Zelira Therapeutics (ASX:ZLD) Secures $1.15M R&D Tax Refund
Zelira Therapeutics (ASX:ZLD) secures a $1.15M refund under the R&D Tax Incentive Scheme to advance clinical programs and business operations.
Opthea Limited (ASX:OPT) Completes Final Patient Visit in Phase 3 COAST Trial
Opthea (ASX:OPT) completes final patient visit in COAST Phase 3 trial, anticipating topline results in early Q2 CY25.
Biome Australia Limited (ASX:BIO) Reports First Net Profit and Unveils Vision 27 Strategic Plan
Biome Australia (ASX:BIO) reports its first net profit in H1 FY25 and launches Vision 27 strategic plan with $75-$85m revenue guidance.
Biome Australia Limited (ASX:BIO) Announces Half-year Results
Biome Australia Limited (ASX:BIO) reports a 47% revenue increase and a net profit of $433k for the half-year ended 31 December 2024.
Althea Group Holdings (ASX:AGH) Secures $4.0M for North America THC Beverage Expansion
Althea Group Holdings (ASX:AGH) raises $4.0 million to expand THC beverage production in North America.
Neurizon Therapeutics Limited (ASX:NUZ) Receives FDA Guidance on NUZ-001 IND Application
Neurizon Therapeutics Limited (ASX:NUZ) receives FDA guidance on its IND application for NUZ-001, requesting additional animal exposure data.
Recce Pharmaceuticals (ASX:RCE) Reports Successful Phase II Trial Results
Recce Pharmaceuticals (ASX:RCE) reports successful Phase II trial of RECCE®327 Gel, advancing to Phase III for ABSSSI treatment.
The Calmer Co International Limited (ASX:CCO) Secures $2.6m FJD Loan for Navua Facility Acquisition
The Calmer Co (ASX:CCO) secures a $2.6m FJD loan for acquiring its Navua facility, enhancing its operational capabilities.
Avecho Biotechnology Limited (ASX:AVE) Addresses Recent Securities Trading
Avecho Biotechnology Limited (ASX:AVE) addresses recent securities trading, citing potential Phase III trial success and confirms compliance with ASX listing rules.